Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China
F-H Zhao, M J Lin, F Chen, S-Y Hu, R Zhang, J L Belinson, J W Sellors, S Franceschi, Y-L Qiao, P E Castle on behalf of Cervical Cancer Screening Group in China
The Lancet Oncology, Published online November 12, 2010 DOI:10.1016/S1470-2045(10)70256-4 11
It is still debated whether high-risk human papillomavirus (HPV) DNA testing could be used as a primary screening method for cervical cancer. An international collaboration, led by the Cancer Institute, Chinese Academy of Medical Sciences and to which IARC took an active part, provided strong support to the accuracy and feasibility of using HPV DNA testing in cervical cancer screening programs in China, as well as in other similar developing countries. Read more
